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Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor
prognostic outcome despite intensive treatment. All chemotherapeutic agents currently
used have no greater than 30–40% response rate, many fall into the range of 10–20%,
with delivery across the blood brain barrier (BBB) or chemoresistance contributing to
the extremely poor outcomes despite treatment. Increased expression of the multidrug
resistance protein 1(MRP1) in high grade glioma, and it’s role in BBB active transport,
highlights this member of the ABC transporter family as a target for improving drug
responses in GBM. In this study we show that small molecule inhibitors and gene
silencing of MRP1 had a significant effect on GBM cell response to temozolomide
(150µM), vincristine (100 nM), and etoposide (2µM). Pre-treatment with Reversan
(inhibitor of MRP1 and P-glycoprotein) led to a significantly improved response to cell
death in the presence of all three chemotherapeutics, in both primary and recurrent
GBM cells. The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein
4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability
over a 72 h period. Specific MRP1 inhibition led to a significant increase in vincristine
and etoposide-induced cell death in all three cell lines assessed. Treatment with MK571,
or specific MRP1 knockdown, did not have any effect on temozolomide drug response
in these cells. These findings have significant implications in providing researchers an
opportunity to improve currently used chemotherapeutics for the initial treatment of
primary GBM, and improved treatment for recurrent GBM patients.
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Introduction
Glioblastoma multiforme (GBM) is a highly aggressive grade IV brain cancer with an extremely
poor prognostic outcome despite intensive treatment regimes. GBM represent approximately 17%
of all primary brain tumors diagnosed worldwide; and 60–75% of astrocytomas, increasing in
frequency with age (WHO and IARC, 2008). Prognosis is reported as “median survival” which,
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for adults with aggressive GBM treated according to the standard
Stupp protocol (Stupp et al., 2005) is 14.6 months. The average
five year survival is less than 3%, leading to the fact that GBM is
the most lethal form of brain tumor.
The standard clinical treatment of newly diagnosed GBM is
known as the Stupp protocol, outlined in 2005 (Stupp et al., 2005)
as radiotherapy (fractionated focal irradiation in daily fractions
of 2 Gy given for 5 days per week for 6 weeks for a total of 60
Gy) in combination with daily temozolomide (TMZ) (75mg/m2
body surface area) administered continuously. Such protocols
increased median survival rates in GBM patients from 12.1
months with RT alone to 14.6 months for TMZ/RT treatment.
Despite surgical resection of GBM tumors, recurrence at distal
sites is typically 6.9 months (Stupp et al., 2005, 2009, 2010) and
in instances where repeat resection is not a viable option, adjunct
chemotherapy is ineffective at stopping tumor progression and
eventually, morbidity. Chemotherapy used for recurrent GBM
includes the PCV regime [procarbazine, CCNU (lomustine),
and vincristine] (Brada et al., 2010) and/or the ACE regime
(bevacizumab combined with carboplatin and etoposide); both
of which are used as palliative therapy in recurrent GBM. All
agents used; however, have no greater than 30–40% response rate
and many fall into the range of 10–20%(Bota et al., 2007) with
delivery or chemoresistance contributing to the extremely poor
patient outcomes despite treatment.
A major hindrance to several chemotherapeutic agents in
effective GBM treatment is their efficient transport across
the blood brain barrier (BBB). For this reason, several
researchers have focused their studies on novel mechanisms
of drug delivery across the BBB and distribution throughout
the brain (Campbell et al., 2008). The role of the BBB
in brain homeostasis is maintained through the action of
active eﬄux transporters of the ATP-binding cassette (ABC)
family including p-glycoprotein (Pgp), the multidrug resistance
proteins (MRPs), and breast cancer resistance protein (BCRP)
(Loscher and Potschka, 2005a,b,c). The significant role which
MRPs play in chemoresistant GBM patients was identified in
1995 by Abe et al. (1994) with high grade gliomas (HGGs)
showing a significant increase in expression of several MRPs
including MRP1 (ABCC1). However, it was the localized
expression of MRP1 within GBM tumor specimens themselves
in addition to the tumor vasculature, identified by Calatozzolo
et al. (2005) which was of particular interest to the authors.
As such, this paper outlines the role of MRP1 inhibition
in improving chemotherapy drug response in both primary
and recurrent GBM patient-biopsy derived cell lines; as
evaluated in vitro, suggesting an intrinsic chemoresistance
role of MRP1 expression in GBM tumor cells, independent
of the B-BB endothelial transport system. In this regard, it
may be suggested that increased MRP1 expression in high
grade gliomas, such as glioblastoma multiforme, contribute to
chemoresistance through increased drug eﬄux and reduced
bioavailability of the administered chemotherapeutic within the
cancerous cell. Improving intracellular exposure to efficient
chemotherapeutics, through MRP1 targeted reduction, would
significantly increase GBM cell death when used in combination
with chemotherapeutic agents.
Materials and Methods
Cell Culture and siRNA Transfections
Commercially available glioblastoma cell lines U251 and A172
(ECACC), glioblastoma cell lines derived from primary tumors,
MZ-327 and MZ-18 and glioblastoma cell lines derived from
recurrent grade IV tumors,MZ-256 andMZ-304 (Hetschko et al.,
2008), were grown as a monolayer in DMEM with 10% heat-
inactivated fetal calf serum, 100 U/ml penicillin, and 100mg/ml
streptomycin and maintained in a humidified incubator at 37◦C
and 5% CO2. For siRNA transfections, cells were seeded at 7 ×
105 cells in a T25 flask (GIBCO) and maintained at 37◦C and
5% CO2 for 24 h. Media was then removed from all flasks in
the dark, and replaced with 5ml of OptiMem media (GIBCO,
UK). Cells were transiently transfected with eitherMRP1-specific
siRNA (GATGACACCTCTCAACAAAdTdT 30 nM) or a non-
targeting negative control siRNA (30 nM, ON-TARGET plus
Non-targeting siRNA#1, Dharmacon, US), using Lipofectamine
2000 (Invitrogen, US) according to manufacturer’s protocol. All
flasks were incubated at 37◦C and 5% CO2 for 96 h.
Protein Extraction and Western Blot Analysis
Transfected cells were washed with phosphate buffered saline
(PBS), trypsinised and cells were centrifuged at 1000 rpm for
3min. The supernatant was then removed and protein was
extracted from cells by resuspending the resulting pellet in
RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 0.2% NP-40,
50mM NaF, 5mM EDTA, 0.1mM orthovanadate, plus protease
inhibitor cocktail SIGMA [P8340]). Resuspended cells in RIPA
were left on ice for 15min before centrifugation at 4◦C and
16,000 rpm for 15min. Protein supernatant was taken from
each sample, quantified and stored at −20◦C. Patient-derived
primary glioblastoma (G6, G8, G12, G38, G39, G43, G44, G59,
and G75), recurrent glioblastoma (G14, G46, G64, and G76),
Oligoastrocytoma (G10), and Gliosarcoma (G22 and G28) lysates
were provided by Mayo Clinic Brain Tumor SPORE (Giannini
et al., 2005; Sarkaria et al., 2006, 2007, 2008).
Western Blotting
Western blot analysis was performed on lysates prepared as
outlined previously. Western blots were carried out using 4–
10% gradient pre-cast gels and HEPES running buffer (PIERCE).
Protein samples were mixed with 10µl of 1xDTT loading
buffer (6x buffer: 4x Tris.Cl/SDS pH6.8, Glycerol 30%, SDS
10%, DTT 0.6 M, Bromophenol Blue 0.012%) and loaded into
gels. Gels were run at 100V for 45min and transferred onto
nitrocellulose membranes at 45V for 90min, using wet transfer
buffer [10x Transfer buffer (100ml), Methanol (200ml), sterile
water (700ml)] [10xTranfers buffer: Tris (30.3 g), glycine (144 g)
Sterile H2O (1000ml)]. Membranes were then blocked in 10%-
milk-TBST overnight at 4◦C. Membranes were incubated with
primary anti-MRP1 antibody (Enzo Life Sciences ALX-801-007-
C125; 1:500) in TBST-milk (0.5%) for 2 h at room temperature.
Membranes were then washed three times with TBST for
5min and secondary anti-rat HRP conjugated antibody (Abcam,
1:5000) was then added for a further 2 h. Loading control protein
beta actin was assessed by incubation of the membrane with
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anti-beta actin antibody (Abcam, 1:5000) in TBST for 1 h at
room temperature. Membranes were then washed in TBST three
times for 5min each, after which a secondary anti-mouse HRP
conjugated antibody (Sigma, 1:5000) was added for 1 h, followed
by further washes with TBST (3 × 5min). All segments were
then developed and the images assessed on a LAS Imager 3000.
Densitometry analysis of protein bands was analyzed using
ImageJ, MRP1 protein bands were normalized to B-actin loading
controls and unpaired Student T-tests were carried out where
appropriate.
Drug Treatment and Metylthiazol Tetrazolium
Assay (MTT) Assay
Glioblastoma cell lines were seeded into a 96 well plate either
directly, or 6 h post transfection with an MRP1-targeting or a
non-targeting negative control siRNA. Cells were seeded onto
96 well plates at a concentration of 1 × 103 cells per well and
incubated for 72 h at 37◦C and 5%CO2 to allowMRP1messenger
RNA suppression to occur. Cells were then treated with either
control media or one of three chemotherapy drugs temozolomide
(150µM), vincristine (100 nM), or etoposide (2µM) (generously
provided by Dr. Markus Rehm). Cells were then returned to
the incubator for a further 72 h; after which time, Metylthiazol
Tetrazolium (MTT) powder in PBS (50µl of 5mg/ml) was added
to each well. Cells were then incubated for a further 4 h after
which all solution was removed and dimethyl sulfoxide (DMSO)
was added. After 10min incubation time at 37◦C, absorbance
was recorded at 570 nm wavelength and data was recorded
and analyzed. Small molecule inhibitors MK571 (25µM) and
Reversan (15µM) were added 7 h prior to carrying out further
drug treatment (temozolomide, vincristine or etoposide) or assay
assessment (media change for proliferation and 2D-migration
assays).
Cell Proliferation Assay
Glioblastoma cells U251, MZ-256, and MZ-327 were pre-
treated with the MRP1 small molecule inhibitor MK571
(M7571 SIGMA) and Reversan (SML0173 SIGMA) at a final
concentration of 25 and 15µM; respectively, for 7 h and
subsequently were seeded at 1 × 104 cells/well in a 6 well plate
and allowed to adhere overnight. Cells were then allowed to grow
for 96 h and counted using the trypan blue exclusion method.
Cell Migration Assay
Glioblastoma cells U251, MZ-256, and MZ-327 were pre-
treated with the MRP1 small molecule inhibitor Reversan
(SML0173 SIGMA) at a final concentration of 15µM for 7 h and
subsequently seeded at 5× 104 cells into wound chambers (Ibidi,
US, Cat#80206) and allowed to adhere overnight. The wound
assay insert was removed, the initial wound was photographed,
cells were allowed to grow for 19–24 h, dependent on cell type,
and then wound closure was re-photographed and assessed
FIGURE 1 | Western Blot of MRP1 expression in commercial,
primary, and recurrent GBM cell lines. Western blot analysis was
performed on lysates prepared from A172, U251, MZ-327, MZ-18,
MZ-256 and MZ-304 glioblastoma cell lines (A) Additionally,
patient-derived primary glioblastoma (G6, G8, G12, G38, G39, G43,
G44, G59, and G75), recurrent glioblastomaU (G14, G46, G64, and
G76), Oligoastrocytoma* (G10), and Gliosarcoma§ (G22 and G28) lysates
were assessed for MRP1 expression (B) Developed membranes showed
MRP1 expression at 190 kDa in varying amounts across the cell lines
assessed.
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using WimScratch Quantitative Wound Healing Image Analysis
(Ibidi, USA).
Results
GBM Cell Lines Drug Response after Small
Molecule Inhibition of MRP1 using MK571 and
Reversan
A variety of glioblastoma multiforme cell lines were chosen for
this study based upon their origins and available clinical data.
Commercially available GBM cell lines A172 and U251, cell lines
derived from primary GBM tumor biopsies (designated MZ-327
and MZ-18), along with cells established from a recurrent tumor
biopsy (MZ-256 and MZ-304) (Hetschko et al., 2008; Murphy
et al., 2014) were used in assessing the effects of pre-treating GBM
cells with MRP1 small molecule inhibitors. All cell lines were
assessed in terms of their MRP1 protein expression when grown
as a monolayer in DMEM media (Figure 1A). Additionally,
patient-derived primary glioblastoma (G6, G8, G12, G38, G39,
G43, G44, G59, and G75), recurrent glioblastoma (G14, G46,
G64, and G76), Oligoastrocytoma (G10), and Gliosarcoma (G22
and G28) lysates were assessed with respect to their MRP1
expression (Figure 1B). To allow analysis across various cell lines,
densitometry analysis of protein bands was carried out using
ImageJ, MRP1 protein bands were normalized to B-actin loading
controls (Supplementary Figures 1A,B). In terms of in vitro
assessment, A172, U251, MZ-327, MZ-18, MZ-256, and MZ-304
were used for evaluation of MRP1 inhibition and chemotherapy
response. Addition of small molecule inhibitors of MRP1 had a
significant effect on GBM cell drug responses to temozolomide,
vincristine, and etoposide. Notably, MK571 is a non-specific
inhibitor ofMRP1, also known to act onMRP4 (Reid et al., 2003);
while Reversan not only inhibits MRP1, but also P-glycoprotein
(Pgp) very effectively (Burkhart et al., 2009; Henderson et al.,
2011). As shown in Figure 2A, inhibition of MRP1 and MRP4 by
MK571 did not lead to a profound change in drug-induced cell
death in any of the commercial cell lines assessed. Pre-treatment
FIGURE 2 | Small Molecule inhibition of MRP1 and
chemoresponse in GBM Commercial cell lines. (A) The effects of
MK571 on temozolomide, vincristine or etoposide-induced cell death in
commercial GBM lines is negligible. MK571 enhanced
vincristine-induced cell death (*p < 0.05) in A172 cells while treatment
of U251 cells with the small molecule MRP1 inhibitor leads to
enhanced temozolomide and vincristine-induced cell death relative to
chemotherapy alone treatment (*p < 0.05). Treatment of A172 and
U251 with Reversan (15µM) leads to a significant increase in
temozolomide, vincristine, and etoposide-induced cell death compared
to chemotherapy drug treatment alone (B) (n = 3 *p < 0.05,
***p < 0.001, Unpaired Student T-test).
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with Reversan however, which would inhibit MRP1 and Pgp, led
to an improved response in terms of temozolomide, vincristine
and etoposide-induced cell death, Figure 2B. The most notably
enhanced cell death was evident in both A172 and U251 cells
treated with a combination of Reversan and vincristine (100 nm).
In the case of primary (MZ-327 and MZ-18, Figure 3A) and
recurrent (MZ-256 and MZ-304, Figure 4A) GBM tumor biopsy
derived cell lines; in both cases the presence of MK571 led to
an enhanced effect of vincristine and etoposide in reducing cell
viability over a 72 h period. MRP1 and MRP4 inhibition by
MK571 did not have any effect on temozolomide drug response
in these cells. Reversan-mediated inhibition of MRP1 and Pgp
led to significant enhancement of temozolomide, vincristine
and etoposide-induced cell death in primary (Figure 3B) and
recurrent (Figure 4B) GBM cell lines.
Specific Inhibition of MRP1 Using
Short-interfering (si)RNA and Drug Response
Assessment
As mentioned previously, due to the non-specific nature of the
small molecule inhibitors currently available to assess MRP1
inhibition in vitro, siRNA were designed which specifically
target MRP1 mRNA; hereby inhibiting protein expression. As
shown in Figure 5A, transient transfection of U251, MZ-18,
and MZ-256 cells led to reduced MRP1 expression after 96 h.
Notably, as shown in lanes 3, 4, 5, and 6 of Figure 5A; MRP1
expression post-transfection is optimal at 96 h, with a noted
re-expression of the target protein by 120 h. This was confirmed
using densitometry analysis of MRP1 protein bands, analyzed
using ImageJ, where MRP1 protein was normalized to B-actin
loading controls and unpaired Student T-tests were carried
FIGURE 3 | Small Molecule inhibition of MRP1 and chemoresponse in
Primary GBM tumor derived cell lines. (A) Treatment of primary
tumor-derived GBM cell lines, MZ-327, and MZ-18, led to a significant
increase in both vincristine and etoposide-induced cell death compared to
chemotherapy treatment alone (n = 3 *p < 0.05, **p < 0.01, ***p < 0.001
Unpaired Student T-test). The presence of MK571 (25µM) did not have any
effect on temozolomide–induced cell death in either of these cell lines.
Treatment with Reversan (15µM) significantly increased cell death for all three
chemotherapies tested (n = 3 *p < 0.05, **p < 0.01 Unpaired Student T-test)
in both lines assessed (B) relative to single chemotherapy drug treatment.
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FIGURE 4 | Small molecule inhibition of MRP1 and chemoresponse in
Recurrent GBM tumor derived cell lines. Treatment of recurrent
tumor-derived GBM cell lines, MZ-304, and MZ-256, led to a significant
increase in both vincristine and etoposide-induced cell death (n = 3
*p < 0.05, **p < 0.01, ***p < 0.001 Unpaired Student T-test) (A) compared
to chemotherapy alone treatment. The presence of MK571 (25µM) did not
have any effect on temozolomide-induced cell death in either of these cell
lines. Treatment with Reversan (15µM), significantly increased cell death for
all three chemotherapies tested (n = 3 *p < 0.05, **p < 0.01, ***p < 0.001
Unpaired Student T-test) in both lines assessed (B).
out to verify target suppression relative to negative control
siRNA treated cell lysates (Supplementary Figure 1C). In this
regard, all further experiments required siRNA treatment to
be carried out, a minimum of, 72 h prior to drug treatment,
thereby ensuring reducing MRP1 expression prior to drug
administration. Figures 5B–D, depict the data obtained from
MTT assays of commercial (U251), primary (MZ-18), and
recurrent (MZ-256) GBM established cell lines. As can be
seen in these figures, specific MRP1siRNA inhibition leads to
a significant reduction in cell viability in all three GBM cell
lines when combined with vincristine (100 nM) or etoposide
(2µM). There was no noted change in response to temozolomide
(150µM) under these conditions, indicating that any effect
noted previously in response to Reversan pre-treatment may be
attributed to Pgp inhibition and not MRP1 targeting. Notably,
all statistical analysis of control vs. treatment; or single vs.
combination treatment groups is represented in Supplementary
Table 2.
Assessment of Alternative Role of MRP1
Inhibition in GBM
Based on previous findings in neuroblastoma cells (Burkhart
et al., 2009; Henderson et al., 2011), the effect of MK571
and Reversan treatment of GBM cells was assessed in vitro.
As depicted in Figures 6A,C,E, there was no alteration in cell
proliferation rates between controls and treated commercial,
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FIGURE 5 | Evaluation of specific MRP1 inhibition using siRNA and the
effect of MRP1 knockdown on chemotherapy-induced cell death.
Glioblastoma cell lines; U251, MZ-18, and MZ-256, representing commercial,
primary tumor derived and recurrent tumor derived glioblastoma cell lines were
transiently transfected with MRP1siRNA. MRP1 protein (190 kDa band) was
reduced in all three cell lines 96 h post-transfection (A). Lane 1: Negative
control siRNA-treated U251, Lane 2: MRP1siRNA-treated U251, Lane 3:
Negative control siRNA-treated MZ-18, Lane 4: MRP1 siRNA-treated MZ-18
after 72 h, Lane 5: MRP1 siRNA-treated MZ-18 after 96 h, Lane 6: MRP1
siRNA-treated MZ-18 after 120 h, Lane 7: Negative control siRNA-treated
MZ-256, Lane 8: MRP1 siRNA-treated MZ-256 after 96 h. The effect of
specific MRP1 inhibition, using siRNA, was evaluated for temozolomide
(150µM), vincristine (100 nM), or etoposide (2µM)– induced cell death and a
significant increase in vincristine and etoposide-induced cell death in all three
cell lines assessed; commercial (B), primary (C), and recurrent (D)-tumor
derived representatives (n = 3 *p < 0.05, ***p < 0.001 Unpaired Student
T-test) relative to single chemotherapy-induced cell death was noted.
primary or recurrent GBM tumor derived lines over a 72 h
period. Additionally, as reduced cell motility was noted in
neuroblastoma cells after exposure to Reversan and with
MRP1siRNA transfection (Henderson et al., 2011), a 2D-
migration or wound closure assay, was carried out 7 h after pre-
treatment of the cells with this small molecule inhibitor (15µM,
Figures 6B,D,F). In the case of glioblastoma cells however,
Reversan treatment did not lead to any change in wound
closure abilities in commercial, primary or recurrent GBM cell
lines.
Discussion
Glioblastoma multiforme is the most aggressive form of brain
cancer with a current median survival post-diagnosis of 14.6
months when treated. The Stupp protocol involves surgery
and concurrent Temozolomide administration with radiotherapy
(Stupp et al., 2005). A major challenge in terms of effective
treatment of brain tumors is penetration of the blood brain
barrier (BBB), a highly selective permeability barrier that
separates the circulating blood from the brain extracellular fluid
in the central nervous system (CNS). The physiology of this
barrier is highly researched in an attempt to provide a means
of ensuring active drug transport and efficient drug delivery
to target regions of the brain. The role of MRP1, along with
other membrane transporters including Pgp, in BBB function
includes the eﬄux of cytotoxic hydrophobic drugs (Regina et al.,
1998). In addition, the fact that MRP1 has been shown to be
highly expressed in high grade glioma patient samples (Benyahia
et al., 2004), with localization of MRP1 to the luminal side
of brain capillary endothelial cells (Nies et al., 2004) suggests
that the efficient eﬄux action of MRP1 in the GBM tumor
microenvironment may contribute to the highly resistant nature
of GBM tumors to current chemotherapeutics. This makes
inhibition ofMRP1 an attractive approach to improve drug influx
to both GBM tumor brain regions and within brain tumor cells.
This study was carried out on a collection of both primary
and recurrent patient-derived GBM tumor biopsy cell lines in
addition to the commercially available U251 and A172 lines with
the aim of identifying the true potential which MRP1 inhibition
may play in primary or recurrent GBM tumor treatment.
Of initial interest was the expression levels of MRP1 protein
in the panel of GBM lines intended for in vitro study and
also patient-derived tumor lysates from primary and recurrent
glioblastoma. As a point of interest, a single oligoastrocytoma
and two gliosarcoma patient tumor-derived lysates were also
included in Western blotting analysis. Notably, the variable
expression noted between individual samples (Figure 1), despite
commonality in tumour stage, in addition to the varied genetic
characteristics of each patient tumor sample (Supplemental Table
1) highlights the heterogeneity of this disease and the need for
a more personalized and direct treatment approach as opposed
to the pan cellular treatment currently employed through use of
chemotherapy.
In addition to evaluating the effects of reduced MRP1
expression on drug resistance in GBM cells, the possibility of
MRP1 playing an alternative role in GBM tumor formation
was also evaluated. Previous findings in neuroblastoma cells
(Burkhart et al., 2009; Henderson et al., 2011) showed that
Reversan was capable of reducing cell motility and colony
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FIGURE 6 | The effect of MK571 and Reversan on cell
proliferation and 2D-migration in commercial, primary, and
recurrent GBM cell lines. Glioblastoma cells U251 (A), MZ-327 (C),
and MZ-256 (E) were pre-incubated with non-specific MRP1 small
molecule inhibitors MK571 (25µM) or Reversan (15µM) and
proliferation and wound-closure capabilities assessed. No significant
change in proliferation was noted in any of the representative cell lines
assessed. Similarly, treatment of glioblastoma cell lines with Reversan
does not alter cell motility in commercial (B), primary (D) and recurrent
(F) GBM cells.
formation devoid of any effect on proliferation rates. In this
regard, we assessed whether non-specific MRP1 inhibition by
Reversan and/or MK571 led to any alteration in wound closure
or proliferation rates in glioblastoma cells. Unlike the case for
neuroblastoma, MRP1 inhibition in this study did not appear to
play any role in cell migration or growth, independent of its role
in drug resistance in GBM cells.
The most notable, and clinically relevant, finding presented
in this publication, through the use of the MRP1 and MRP4
small molecule inhibitor, MK571, and also an MRP1 specific
siRNA, is that MRP1 inhibition enhanced Vincristine- and
Etoposide-, but not Temozolomide-induced cell death in primary
or recurrent GBM cell lines. Inhibition of MRP1 and Pgp, using
Reversan (15µM), and subsequent treatment with temozolomide
(150µM) however led to a statistically significant increase in
cell death compared to temozolomide treatment alone across
all primary, recurrent and commercial cell lines assessed in
this study. In 2013, Veringa et al. (2013) detailed a list of
substrate specificity for classical therapeutics for a range of eﬄux
transporters, including MRP1 and Pgp. In their findings they
list that temozolomide is a substrate for Pgp and Breast cancer
related protein (BCRP) but not MRP1. Additionally, our findings
corroborate Peignan et al. (2011), who note a lack of effect on cell
death in the commercial GBM line T98G whenMRP1 siRNAwas
used in vitro.
Vincristine and etoposide are two additional chemotherapies
which are currently used in recurrent GBM treatment regimens
as a means of palliative care, therefore the clinical application
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of assessing their improved efficacy was of great interest in
both primary and recurrent GBM cell lines. MRP1 inhibition
using MK571, Reversan and MRP1siRNA led to a significant
enhancement in the cell death capabilities of both vincristine
(100 nM) and etoposide (2µM). In terms of MK571 use,
neither etoposide nor vincristine are MRP4 substrates (Dallas
et al., 2004), however both are known to be MRP1 substrates
(Veringa et al., 2013). This, in addition to the use of an
MRP1-specific siRNA devoid of off-target effects proves that the
specific inhibition of the MRP1 transporter protein allows both
vincristine (100 nM) and etoposide (2µM) to induce cell death
more effectively in GBM cells in vitro.
The findings of this study have significant implications in
terms of providing researchers an opportunity to improve
currently used chemotherapeutics for the initial treatment of
primary GBM, and improved treatment for recurrent GBM
patients. Additionally, the data obtained during this study
is highly significant for further in vivo assessment of GBM
orthotopic murine models of chemoresistance.
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